Mar 01, 2022

Starpharma’s (ASX:SPL) nasal spray outperforms competitors against Omicron variant

Starpharma’s (ASX:SPL) nasal spray outperforms competitors against Omicron variant

"Starpharma’s (SPL) antiviral nasal spray has achieved a greater than 99.5 per cent reduction of virus infectivity against the Omicron variant of SARS-CoV-2." The Market Herald reports on Starpharma, following the company's latest announcement. Read the article here

 This contains certain forward-looking statements.